StreetInsider.com News Articles

Form 144 HALOZYME THERAPEUTICS, Filed by: Connaughton Bernadette

Mon, 10 Aug 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260810/26898579.html

Form 144 HALOZYME THERAPEUTICS, Filed by: Connaughton Bernadette

Mon, 10 Aug 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260810/26898579.html

Halozyme Therapeutics (HALO) PT Raised to $105 at TD Cowen

Fri, 07 Aug 2026 08:52:10 -0400

TD Cowen analyst Brendan Smith raised the price target on Halozyme Therapeutics (NASDAQ: HALO) to $105.00 (from $96.00) while maintaining a Buy rating.

Halozyme Therapeutics (HALO) PT Raised to $95 at Wells Fargo

Fri, 07 Aug 2026 08:19:01 -0400

Wells Fargo analyst Mohit Bansal raised the price target on Halozyme Therapeutics (NASDAQ: HALO) to $95.00 (from $75.00) while maintaining a Equal Weight rating.

Halozyme Therapeutics (HALO) PT Raised to $93 at Citizens on Royalty Revenue Growth

Fri, 07 Aug 2026 07:32:38 -0400

Citizens analyst Jason Butler raised the price target on Halozyme Therapeutics (NASDAQ: HALO) to $93.00 (from $92.00) while maintaining a Market Outperform rating.

The analyst commented, "New commercial products drive meaningful growth in royalty revenue; we reiterate our Market Outperform rating and increase our risk-adjusted, DCF-derived price target to $93 from $92 on Halozyme. Yesterday afternoon, Halozyme reported 2Q26 financial results ahead of our and consensus estimates, driven by yet another quarter of strong royalty growth. The company increased guidance for 2026 driven by early momentum of new commercial products. Beyond the continued growth of the commercial portfolio, in our view,

Halozyme Therapeutics (HALO) PT Raised to $93 at Citizens on Royalty Revenue Growth

Fri, 07 Aug 2026 07:32:38 -0400

Citizens analyst Jason Butler raised the price target on Halozyme Therapeutics (NASDAQ: HALO) to $93.00 (from $92.00) while maintaining a Market Outperform rating.

Leerink Upgrades Halozyme Therapeutics (HALO) to Outperform

Fri, 07 Aug 2026 07:02:41 -0400

Leerink analyst David Risinger upgraded Halozyme Therapeutics (NASDAQ: HALO) from Market Perform to Outperform with a price target of $110.00 (from $83.00).

For an analyst ratings summary and ratings history on Halozyme Therapeutics click here. For more ratings news on Halozyme Therapeutics click here.

Shares of Halozyme Therapeutics closed at $85.76 yesterday.

Halozyme Therapeutics (HALO) Tops Q2 EPS by 47c; raises guidance

Thu, 06 Aug 2026 16:30:26 -0400

Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of $2.28, $0.47 better than the analyst estimate of $1.81. Revenue for the quarter came in at $481 million versus the consensus estimate of $401.27 million.

GUIDANCE:

Halozyme Therapeutics sees FY2026 EPS of $8.65-$9.00, versus the consensus of $8.10. Halozyme Therapeutics sees FY2026 revenue of $1.835-1.910 billion, versus the consensus of $1.768 billion.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.

Halozyme Therapeutics (HALO) Tops Q2 EPS by 47c; raises guidance

Thu, 06 Aug 2026 16:30:26 -0400

GUIDANCE:

Halozyme Therapeutics sees FY2026 EPS of $8.65-$9.00, versus the consensus of $8.10. Halozyme Therapeutics sees FY2026 revenue of $1.835-1.910 billion, versus the consensus of $1.768 billion.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.

Form 10-Q HALOZYME THERAPEUTICS, For: Jun 30

Thu, 06 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260806/26884062.html

Form 10-Q HALOZYME THERAPEUTICS, For: Jun 30

Thu, 06 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260806/26884062.html

Form 8-K HALOZYME THERAPEUTICS, For: Aug 06

Thu, 06 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260806/26883837.html

Form 8-K HALOZYME THERAPEUTICS, For: Aug 06

Thu, 06 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260806/26883837.html

HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE

Thu, 06 Aug 2026 16:01:00 -0400

Total Revenue Increased 48% YOY to $481 million
Royalty Revenue Increased 50% YOY to $308 million

Raises 2026 Financial Guidance Ranges:
Total Revenue of $1.835 - $1.910 billion, YOY Growth of 31% - 37%
Royalty Revenue of $1.220 - $1.245 billion, YOY Growth of 41% - 43%
Adjusted EBITDA of $1.225 - $1.280 billion, YOY Growth of 86% - 95%¹Non-GAAP Diluted EPS of $8.65 - $9.00, YOY Growth of 108% - 117%¹